Although initially approved for the treatment of type 2 diabetes mellitus, glucagon-like peptide 1 (GLP-1) receptor agonists have moved into the mainstream as pharmacologic adjuncts for weight loss, with proven safety and efficacy in patients with and without diabetes [12]. The gene discussed is GCG; the disease is diabetes mellitus.